Picture loading failed.

Anti-TNFRSF10B therapeutic antibody (Pre-made Tigatuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer, Phase II trials for colorectal cancer, non-small cell lung cancer, and ovarian cancer have been completed.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-571-1mg 1mg 3090
GMP-Bios-ab-571-10mg 10mg 21890
GMP-Bios-ab-571-100mg 100mg 148000
GMP-Bios-ab-571-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TNFRSF10B therapeutic antibody (Pre-made Tigatuzumab biosimilar,Whole mAb)
INN Name Tigatuzumab
TargetTNFRSF10B
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2007
Year Recommended2008
CompaniesDaiichi Sankyo Company;University of Alabama at Birmingham
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer;Colorectal cancer;Liver cancer;Lymphoma;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer
Development Techna